Anixa Biosciences (ANIX) Competitors

$2.79 0.00 (0.00%)

As of 05/22/2026 04:00 PM Eastern

ANIX vs. GLSI, LRMR, XFOR, ALT, and CABA

Should you buy Anixa Biosciences stock or one of its competitors? MarketBeat compares Anixa Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Anixa Biosciences include Greenwich LifeSciences (GLSI), Larimar Therapeutics (LRMR), X4 Pharmaceuticals (XFOR), Altimmune (ALT), and Cabaletta Bio (CABA). These companies are all part of the "pharmaceutical products" industry.

How does Anixa Biosciences compare to Greenwich LifeSciences?

Anixa Biosciences (NASDAQ:ANIX) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Anixa Biosciences has higher revenue and earnings than Greenwich LifeSciences. Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Anixa Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A
Greenwich LifeSciences	N/A	N/A	-$15.79M	-$1.46	N/A

Anixa Biosciences has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market. Comparatively, Greenwich LifeSciences has a beta of 1.39, suggesting that its share price is 39% more volatile than the broader market.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Greenwich LifeSciences had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 2 mentions for Greenwich LifeSciences and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.00 equaled Greenwich LifeSciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Greenwich LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences' return on equity of -70.95% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
Greenwich LifeSciences	N/A	-1,042.84%	-565.43%

Anixa Biosciences currently has a consensus price target of $8.50, indicating a potential upside of 204.66%. Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 71.79%. Given Anixa Biosciences' higher possible upside, analysts plainly believe Anixa Biosciences is more favorable than Greenwich LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Anixa Biosciences beats Greenwich LifeSciences on 8 of the 12 factors compared between the two stocks.

How does Anixa Biosciences compare to Larimar Therapeutics?

Anixa Biosciences (NASDAQ:ANIX) and Larimar Therapeutics (NASDAQ:LRMR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 91.9% of Larimar Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 4.5% of Larimar Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Larimar Therapeutics had 5 more articles in the media than Anixa Biosciences. MarketBeat recorded 6 mentions for Larimar Therapeutics and 1 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 0.00 beat Larimar Therapeutics' score of -0.23 indicating that Anixa Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Larimar Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anixa Biosciences currently has a consensus target price of $8.50, suggesting a potential upside of 204.66%. Larimar Therapeutics has a consensus target price of $16.33, suggesting a potential upside of 373.43%. Given Larimar Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Larimar Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Larimar Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10

Anixa Biosciences has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market. Comparatively, Larimar Therapeutics has a beta of 0.91, meaning that its share price is 9% less volatile than the broader market.

Anixa Biosciences' return on equity of -70.95% beat Larimar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
Larimar Therapeutics	N/A	-134.14%	-96.00%

Anixa Biosciences has higher revenue and earnings than Larimar Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Larimar Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A
Larimar Therapeutics	N/A	N/A	-$165.67M	-$2.06	N/A

Summary

Larimar Therapeutics beats Anixa Biosciences on 8 of the 15 factors compared between the two stocks.

How does Anixa Biosciences compare to X4 Pharmaceuticals?

X4 Pharmaceuticals (NASDAQ:XFOR) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

Anixa Biosciences has lower revenue, but higher earnings than X4 Pharmaceuticals. Anixa Biosciences is trading at a lower price-to-earnings ratio than X4 Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
X4 Pharmaceuticals	$35.11M	10.85	-$79.20M	-$4.54	N/A
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A

X4 Pharmaceuticals currently has a consensus price target of $8.50, suggesting a potential upside of 110.40%. Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 204.66%. Given Anixa Biosciences' higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than X4 Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
X4 Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, X4 Pharmaceuticals and X4 Pharmaceuticals both had 1 articles in the media. X4 Pharmaceuticals' average media sentiment score of 0.00 equaled Anixa Biosciences'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
X4 Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

72.0% of X4 Pharmaceuticals shares are owned by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are owned by institutional investors. 1.1% of X4 Pharmaceuticals shares are owned by company insiders. Comparatively, 26.4% of Anixa Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

X4 Pharmaceuticals has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market.

Anixa Biosciences has a net margin of 0.00% compared to X4 Pharmaceuticals' net margin of -1,106.30%. Anixa Biosciences' return on equity of -70.95% beat X4 Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
X4 Pharmaceuticals	-1,106.30%	-94.90%	-48.09%
Anixa Biosciences	N/A	-70.95%	-62.53%

Summary

Anixa Biosciences beats X4 Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Anixa Biosciences compare to Altimmune?

Altimmune (NASDAQ:ALT) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

In the previous week, Altimmune had 9 more articles in the media than Anixa Biosciences. MarketBeat recorded 10 mentions for Altimmune and 1 mentions for Anixa Biosciences. Altimmune's average media sentiment score of 0.91 beat Anixa Biosciences' score of 0.00 indicating that Altimmune is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Altimmune	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

78.1% of Altimmune shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Comparatively, 26.4% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Altimmune currently has a consensus price target of $16.67, suggesting a potential upside of 474.71%. Anixa Biosciences has a consensus price target of $8.50, suggesting a potential upside of 204.66%. Given Altimmune's stronger consensus rating and higher probable upside, research analysts plainly believe Altimmune is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Altimmune	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Anixa Biosciences has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Anixa Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Altimmune	-214,860.98%	-42.57%	-35.57%
Anixa Biosciences	N/A	-70.95%	-62.53%

Altimmune has a beta of 0.18, suggesting that its share price is 82% less volatile than the broader market. Comparatively, Anixa Biosciences has a beta of 0.64, suggesting that its share price is 36% less volatile than the broader market.

Anixa Biosciences has higher revenue and earnings than Altimmune. Anixa Biosciences is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Altimmune	$40K	14,099.08	-$88.09M	-$0.93	N/A
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A

Summary

Altimmune beats Anixa Biosciences on 10 of the 16 factors compared between the two stocks.

How does Anixa Biosciences compare to Cabaletta Bio?

Anixa Biosciences (NASDAQ:ANIX) and Cabaletta Bio (NASDAQ:CABA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Cabaletta Bio had 1 more articles in the media than Anixa Biosciences. MarketBeat recorded 2 mentions for Cabaletta Bio and 1 mentions for Anixa Biosciences. Cabaletta Bio's average media sentiment score of 0.50 beat Anixa Biosciences' score of 0.00 indicating that Cabaletta Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anixa Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cabaletta Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Anixa Biosciences has a beta of 0.64, indicating that its share price is 36% less volatile than the broader market. Comparatively, Cabaletta Bio has a beta of 3.18, indicating that its share price is 218% more volatile than the broader market.

Anixa Biosciences presently has a consensus target price of $8.50, indicating a potential upside of 204.66%. Cabaletta Bio has a consensus target price of $15.50, indicating a potential upside of 324.66%. Given Cabaletta Bio's stronger consensus rating and higher possible upside, analysts plainly believe Cabaletta Bio is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Cabaletta Bio	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Anixa Biosciences has higher revenue and earnings than Cabaletta Bio. Anixa Biosciences is trading at a lower price-to-earnings ratio than Cabaletta Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	445.47	-$10.93M	-$0.33	N/A
Cabaletta Bio	N/A	N/A	-$167.86M	-$1.96	N/A

Anixa Biosciences' return on equity of -70.95% beat Cabaletta Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-70.95%	-62.53%
Cabaletta Bio	N/A	-131.58%	-96.46%

29.1% of Anixa Biosciences shares are owned by institutional investors. 26.4% of Anixa Biosciences shares are owned by insiders. Comparatively, 6.4% of Cabaletta Bio shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Anixa Biosciences and Cabaletta Bio tied by winning 7 of the 14 factors compared between the two stocks.

Get Anixa Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANIX vs. The Competition

Export

Metric	Anixa Biosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$93.54M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-8.45	18.74	21.21	25.65
Price / Sales	445.47	323.98	554.38	86.31
Price / Cash	N/A	125.17	43.49	56.67
Price / Book	6.64	7.09	10.37	7.14
Net Income	-$10.93M	$24.45M	$3.57B	$335.98M
7 Day Performance	4.49%	6.38%	6.40%	4.15%
1 Month Performance	-8.52%	2.43%	3.53%	2.54%
1 Year Performance	11.60%	62.98%	34.04%	35.06%

Anixa Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANIX Anixa Biosciences	1.8948 of 5 stars	$2.79 flat	$8.50 +204.7%	+11.6%	$93.54M	$210K	N/A	5	Upcoming Earnings
GLSI Greenwich LifeSciences	1.1652 of 5 stars	$26.88 -1.2%	$47.50 +76.7%	+181.9%	$376.98M	N/A	N/A	3	Positive News
LRMR Larimar Therapeutics	3.4444 of 5 stars	$3.24 -9.5%	$16.33 +404.1%	+84.5%	$371.90M	N/A	N/A	30	Gap Up
XFOR X4 Pharmaceuticals	2.197 of 5 stars	$3.68 -6.6%	$8.50 +131.0%	+30.3%	$371.62M	$35.11M	N/A	80
ALT Altimmune	3.7182 of 5 stars	$2.80 -1.8%	$16.67 +495.2%	-49.2%	$370.80M	$40K	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANIX) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anixa Biosciences (ANIX) Competitors

ANIX vs. GLSI, LRMR, XFOR, ALT, and CABA

How does Anixa Biosciences compare to Greenwich LifeSciences?

Summary

How does Anixa Biosciences compare to Larimar Therapeutics?

Summary

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Summary

How does Anixa Biosciences compare to Altimmune?

Summary

How does Anixa Biosciences compare to Cabaletta Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anixa Biosciences (ANIX) Competitors

ANIX vs. GLSI, LRMR, XFOR, ALT, and CABA

How does Anixa Biosciences compare to Greenwich LifeSciences?

Which has higher valuation & earnings, ANIX or GLSI?

Which has more risk & volatility, ANIX or GLSI?

Do insiders and institutionals believe in ANIX or GLSI?

Does the media prefer ANIX or GLSI?

Is ANIX or GLSI more profitable?

Do analysts prefer ANIX or GLSI?

Summary

How does Anixa Biosciences compare to Larimar Therapeutics?

Do institutionals & insiders have more ownership in ANIX or LRMR?

Does the media refer more to ANIX or LRMR?

Do analysts prefer ANIX or LRMR?

Which has more volatility & risk, ANIX or LRMR?

Is ANIX or LRMR more profitable?

Which has better valuation and earnings, ANIX or LRMR?

Summary

How does Anixa Biosciences compare to X4 Pharmaceuticals?

Which has better valuation & earnings, XFOR or ANIX?

Do analysts recommend XFOR or ANIX?

Does the media refer more to XFOR or ANIX?

Do institutionals and insiders have more ownership in XFOR or ANIX?

Which has more volatility & risk, XFOR or ANIX?

Is XFOR or ANIX more profitable?

Summary

How does Anixa Biosciences compare to Altimmune?

Does the media favor ALT or ANIX?

Do institutionals & insiders hold more shares of ALT or ANIX?

Do analysts prefer ALT or ANIX?

Is ALT or ANIX more profitable?

Which has more volatility & risk, ALT or ANIX?

Which has higher valuation and earnings, ALT or ANIX?

Summary

How does Anixa Biosciences compare to Cabaletta Bio?

Does the media prefer ANIX or CABA?

Which has more risk and volatility, ANIX or CABA?

Do analysts prefer ANIX or CABA?

Which has better valuation & earnings, ANIX or CABA?

Is ANIX or CABA more profitable?

Do institutionals and insiders believe in ANIX or CABA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANIX vs. The Competition

Anixa Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools